Synlogic announces advancement of synb1891 to combination arm dosing with pd-l1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma

Cambridge, mass., dec. 14, 2020 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced synb1891 has advanced into the combination therapy stage of the ongoing phase 1 trial. synb1891...
SYBX Ratings Summary
SYBX Quant Ranking